SCHEMBL24027892

SCHEMBL24027892

COc1cnc(C=O)cc1-c1c(C)cccc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 2/20 0.39
▸ FDPS P14324 1/20 0.36
▸ FGFR1 P11362 2/20 0.35
▸ ALDH1A1 P00352 5/20 0.34
▸ TLR2 O60603 1/20 0.34
▸ ERN1 O75460 1/20 0.34
▸ TLR1 Q15399 1/20 0.34
▸ TLR6 Q9Y2C9 1/20 0.34
▸ APAF1 O14727 1/20 0.34
▸ MITF O75030 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ PDPK1 O15530 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ LCK P06239 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136393 0.77 FDPS (0.40) FDPSALDH1A1ERN1MAPTMEN1
SCHEMBL24027999 0.77 FFAR1 (0.42) FFAR1FGFR1ALDH1A1LMNAMAPT
SCHEMBL24027982 0.77 FGFR1 (0.40) FFAR1FGFR1ALDH1A1LMNAMAPT
SCHEMBL4152949 0.74 FDPS (0.40) FDPSALDH1A1ERN1LMNAMAPT
SCHEMBL2019514 0.74 ALDH1A1 (0.56) FFAR1FDPSALDH1A1LMNAMAPT
SCHEMBL24027861 0.73 FFAR1 (0.41) FFAR1FGFR1ALDH1A1LMNAMEN1
SCHEMBL1223854 0.73 ALDH1A1 (0.47) FDPSALDH1A1LMNAMAPTHTT
SCHEMBL24027942 0.72 ALDH1A1 (0.43) FFAR1FGFR1ALDH1A1TLR2ERN1
SCHEMBL30212976 0.72 ALDH1A1 (0.43) FFAR1FGFR1ALDH1A1TLR2ERN1
SCHEMBL30011114 0.71 FFAR1 (0.42) FFAR1ALDH1A1APAF1MITFLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 — — US disclosed
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 — — US disclosed
CN-115697974-A Imidazole 3-oxide derivative based ACSS2 inhibitors and methods of use thereof 美特波米德有限公司 2023-02-03 — — CN disclosed
WO-2021229571-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2021-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 FFAR1 1183/4885FDPS 1296/4885FGFR1 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback